Show simple item record

dc.contributor.authorO’ Reilly, Eimear
dc.contributor.authorTirincsi, Andrea
dc.contributor.authorLogue, Susan E.
dc.contributor.authorSzegezdi, Eva
dc.date.accessioned2018-09-20T16:22:38Z
dc.date.available2018-09-20T16:22:38Z
dc.date.issued2016-10-31
dc.identifier.citationO’ Reilly, Eimear; Tirincsi, Andrea; Logue, Susan E. Szegezdi, Eva (2016). The janus face of death receptor signaling during tumor immunoediting. Frontiers in Immunology 7 ,
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/10379/13623
dc.description.abstractCancer immune surveillance is essential for the inhibition of carcinogenesis. Malignantly transformed cells can be recognized by both the innate and adaptive immune systems through different mechanisms. Immune effector cells induce extrinsic cell death in the identified tumor cells by expressing death ligand cytokines of the tumor necrosis factor ligand family. However, some tumor cells can escape immune elimination and progress. Acquisition of resistance to the death ligand-induced apoptotic pathway can be obtained through cleavage of effector cell expressed death ligands into a poorly active form, mutations or silencing of the death receptors, or overexpression of decoy receptors and pro-survival proteins. Although the immune system is highly effective in the elimination of malignantly transformed cells, abnormal/dysfunctional death ligand signaling curbs its cytotoxicity. Moreover, DRs can also transmit pro-survival and pro-migratory signals. Consequently, dysfunctional death receptor-mediated apoptosis/necroptosis signaling does not only give a passive resistance against cell death but actively drives tumor cell motility, invasion, and contributes to consequent metastasis. This dual contribution of the death receptor signaling in both the early, elimination phase, and then in the late, escape phase of the tumor immunoediting process is discussed in this review. Death receptor agonists still hold potential for cancer therapy since they can execute the tumor-eliminating immune effector function even in the absence of activation of the immune system against the tumor. The opportunities and challenges of developing death receptor agonists into effective cancer therapeutics are also discussed.
dc.publisherFrontiers Media SA
dc.relation.ispartofFrontiers in Immunology
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjecttnf-related apoptosis-inducing ligand (trail)
dc.subjectfas (cd95)
dc.subjectapoptosis
dc.subjectnecroptosis
dc.subjectpro-survival signaling
dc.subjectimmune surveillance
dc.subjectcancer
dc.subjectapoptosis-inducing ligand
dc.subjectnf-kappa-b
dc.subjecttrail-induced apoptosis
dc.subjectkiller-cell activation
dc.subjectlung-cancer cells
dc.subjecthuman nk cells
dc.subjectnecrosis-factor
dc.subjectfas ligand
dc.subjectt-cells
dc.subjectc-flip
dc.titleThe janus face of death receptor signaling during tumor immunoediting
dc.typeArticle
dc.identifier.doi10.3389/fimmu.2016.00446
dc.local.publishedsourcehttp://journal.frontiersin.org/article/10.3389/fimmu.2016.00446/pdf
nui.item.downloads0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland